DK0960105T3 - Benzofurazanforbindelser, der foröger AMPA-receptoraktivitet - Google Patents

Benzofurazanforbindelser, der foröger AMPA-receptoraktivitet

Info

Publication number
DK0960105T3
DK0960105T3 DK98906358T DK98906358T DK0960105T3 DK 0960105 T3 DK0960105 T3 DK 0960105T3 DK 98906358 T DK98906358 T DK 98906358T DK 98906358 T DK98906358 T DK 98906358T DK 0960105 T3 DK0960105 T3 DK 0960105T3
Authority
DK
Denmark
Prior art keywords
compounds
ampa receptor
receptor activity
receptors
ampa
Prior art date
Application number
DK98906358T
Other languages
Danish (da)
English (en)
Inventor
Gary A Rogers
Christopher M Marrs
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK0960105T3 publication Critical patent/DK0960105T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Furan Compounds (AREA)
  • Luminescent Compositions (AREA)
DK98906358T 1997-02-13 1998-02-13 Benzofurazanforbindelser, der foröger AMPA-receptoraktivitet DK0960105T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/800,108 US6110935A (en) 1997-02-13 1997-02-13 Benzofurazan compounds for enhancing glutamatergic synaptic responses

Publications (1)

Publication Number Publication Date
DK0960105T3 true DK0960105T3 (da) 2004-08-30

Family

ID=25177504

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98906358T DK0960105T3 (da) 1997-02-13 1998-02-13 Benzofurazanforbindelser, der foröger AMPA-receptoraktivitet
DK04075259T DK1428534T3 (da) 1997-02-13 1998-02-13 Benzofurazanderivater til forögelse af glutaminerge synaptiske responser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04075259T DK1428534T3 (da) 1997-02-13 1998-02-13 Benzofurazanderivater til forögelse af glutaminerge synaptiske responser

Country Status (24)

Country Link
US (3) US6110935A (fr)
EP (2) EP1428534B1 (fr)
JP (1) JP4446023B2 (fr)
KR (1) KR100544295B1 (fr)
CN (1) CN1085206C (fr)
AT (2) ATE326221T1 (fr)
AU (1) AU737802C (fr)
BR (1) BR9807333B1 (fr)
CA (1) CA2279319C (fr)
CZ (1) CZ299765B6 (fr)
DE (2) DE69834590T2 (fr)
DK (2) DK0960105T3 (fr)
ES (2) ES2264078T3 (fr)
GB (1) GB2325225B (fr)
HU (1) HUP0002303A3 (fr)
ID (1) ID22342A (fr)
IL (1) IL131200A (fr)
NO (1) NO318935B1 (fr)
NZ (1) NZ336980A (fr)
PL (1) PL199135B1 (fr)
PT (2) PT1428534E (fr)
RU (1) RU2189984C2 (fr)
TR (1) TR199901941T2 (fr)
WO (1) WO1998035950A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188837B (fr) * 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
AU2002366756A1 (en) * 2001-12-20 2003-07-09 Alangudi Sankaranarayanan Use of benzofuroxan derivatives as antiplatelet agents
AU2004204814B2 (en) * 2003-01-13 2009-10-08 Cortex Pharmaceuticals, Inc. Method of treating cognitive decline due to sleep deprivation and stress
US7385061B2 (en) * 2003-05-23 2008-06-10 Basilea Pharmaceutica Ag Furazanobenzimidazoles
JP2007519733A (ja) * 2004-01-26 2007-07-19 コーテックス ファーマシューティカルズ インコーポレーティッド アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
MX2009002180A (es) * 2006-08-31 2009-06-05 Univ Alberta Metodo de inhibicion de la depresion respiratoria mediante el uso de moduladores alostericos positivos del receptor ampa.
BRPI0720749A2 (pt) * 2007-01-03 2014-01-14 Cortex Pharma Inc Composto de [1,2,3]-benzotriazinona 3-substituído, composição farmacêutica e uso de referido composto
JP2010514837A (ja) * 2007-01-03 2010-05-06 コーテックス ファーマシューティカルズ， インコーポレイテッド グルタミン酸作動性シナプス反応を強化するための３−置換−［１，２，３］ベンゾトリアジノン化合物
AU2008254960B2 (en) 2007-05-17 2014-11-27 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
ES2560095T3 (es) * 2007-08-10 2016-02-17 Cortex Pharmaceuticals, Inc. Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
WO2010054336A2 (fr) * 2008-11-10 2010-05-14 The Regents Of The University Of California Utilisations thérapeutiques de modulateurs du récepteur ampa pour le traitement d'un dysfonctionnement moteur
MX2011008060A (es) * 2009-02-02 2011-09-09 Cortex Pharma Inc Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas.
EP2544688B1 (fr) 2010-03-02 2016-09-07 President and Fellows of Harvard College Procédés et compositions pour le traitement du syndrome d'angelman
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
CA2829006A1 (fr) 2011-03-04 2012-09-13 The Regents Of The University Of California Facteurs de croissance liberes localement pour favoriser la recuperation motrice apres un accident vasculaire cerebral
CN102633731B (zh) * 2012-03-13 2014-04-30 四川大学华西医院 6-喹喔啉甲酸酰胺化合物、制备方法和应用
KR101421032B1 (ko) * 2012-12-28 2014-07-22 주식회사 레고켐 바이오사이언스 (2-메틸-1-(3-메틸벤질)-1Ｈ-벤조[d]이미다졸-5일)(피페리딘-5-일)메탄온의 제조방법
CN105579575A (zh) 2013-06-13 2016-05-11 维罗技术有限责任公司 用于治疗代谢失调的组合物和方法
CN107286114B (zh) 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
FR2499991A1 (fr) * 1981-02-19 1982-08-20 Sandoz Sa Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments
US4420485A (en) * 1982-09-29 1983-12-13 Hoechst-Roussel Pharmaceuticals Inc. 1'-[3-(1,2-Benzisoxazol-3-yl) proply]spiro[benzofuran-2(3H),3' or 4'-piperidines or 3'-pyrrolidines]
US5032604A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US5112824A (en) * 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
DK1156043T3 (da) * 1992-07-24 2004-03-01 Univ California Lægemidler, der forøger synaptiske reaktioner formidlet af ampa-receptorer
ATE174915T1 (de) * 1994-10-31 1999-01-15 Merck Patent Gmbh Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response

Also Published As

Publication number Publication date
CA2279319A1 (fr) 1998-08-20
NO318935B1 (no) 2005-05-30
IL131200A (en) 2005-06-19
NO993768D0 (no) 1999-08-04
KR20000071082A (ko) 2000-11-25
BR9807333A (pt) 2000-04-18
NO993768L (no) 1999-09-23
NZ336980A (en) 2000-08-25
GB2325225B (en) 1999-03-03
EP1428534B1 (fr) 2006-05-17
DE69823803T2 (de) 2005-04-14
RU2189984C2 (ru) 2002-09-27
PL335058A1 (en) 2000-03-27
AU737802B2 (en) 2001-08-30
CA2279319C (fr) 2008-08-05
GB9809221D0 (fr) 1998-07-01
BR9807333B1 (pt) 2011-10-18
KR100544295B1 (ko) 2006-01-23
EP0960105B1 (fr) 2004-05-12
EP1428534A1 (fr) 2004-06-16
CN1085206C (zh) 2002-05-22
PT1428534E (pt) 2006-07-31
IL131200A0 (en) 2001-01-28
DK1428534T3 (da) 2006-06-12
PT960105E (pt) 2004-09-30
GB2325225A8 (en) 1999-02-17
CN1247534A (zh) 2000-03-15
CZ299765B6 (cs) 2008-11-19
JP2001512459A (ja) 2001-08-21
PL199135B1 (pl) 2008-08-29
US6110935A (en) 2000-08-29
DE69823803D1 (de) 2004-06-17
TR199901941T2 (xx) 1999-12-21
ID22342A (id) 1999-09-30
ATE266649T1 (de) 2004-05-15
DE69834590T2 (de) 2007-04-26
EP0960105A1 (fr) 1999-12-01
US6313115B1 (en) 2001-11-06
ATE326221T1 (de) 2006-06-15
US6730677B2 (en) 2004-05-04
US20020055508A1 (en) 2002-05-09
JP4446023B2 (ja) 2010-04-07
GB2325225A (en) 1998-11-18
ES2264078T3 (es) 2006-12-16
DE69834590D1 (de) 2006-06-22
AU737802C (en) 2005-05-12
CZ279599A3 (cs) 2000-01-12
HUP0002303A2 (hu) 2001-04-28
HUP0002303A3 (en) 2002-09-30
ES2221152T3 (es) 2004-12-16
AU6159998A (en) 1998-09-08
WO1998035950A1 (fr) 1998-08-20

Similar Documents

Publication Publication Date Title
DK0960105T3 (da) Benzofurazanforbindelser, der foröger AMPA-receptoraktivitet
DK0891365T3 (da) Benzoxaziner til forstærkning af synaptiske responser
DE69811363D1 (de) Piperazin-derivate und ihre verwendung als entzündungshemmende mittel
DE69920497D1 (de) Liponsaürederivate und deren verwendung bei der behandlung von krankheiten
PT839134E (pt) Benzoilpiperidinas/pirrolidinas para melhoramento da resposta sinaptica
DE69435303D1 (de) Er behandlung von krankheiten bei denen eine cytok
DK1054673T3 (da) Benzoxazinforbindelser til forstærkelse af synaptisk reaktion
DK1067935T3 (da) Acylbenzoxaziner til forstærkning af synaptisk(e) reaktion(er)
EA200400584A1 (ru) Соединения карбонилбензоксазина для усиления глутаматергических синаптических ответов
BR0015402A (pt) Derivados de ácido 15-hidroxieicosatetraenóico de cadeia Èmega modificada e métodos de seu uso para o tratamento de olho seco
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
TH28200B (th) การใช้ (สูตร) il -อะโกนิสท์สำหรับรักษาการกลั้นปัสสาวะไม่อยู่